Candidiasis - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Candidiasis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Candidiasis - Pipeline Review, H1 2016', provides an overview of the Candidiasis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Candidiasis Overview 8
Therapeutics Development 9
Pipeline Products for Candidiasis - Overview 9
Pipeline Products for Candidiasis - Comparative Analysis 10
Candidiasis - Therapeutics under Development by Companies 11
Candidiasis - Therapeutics under Investigation by Universities/Institutes 13
Candidiasis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Candidiasis - Products under Development by Companies 18
Candidiasis - Products under Investigation by Universities/Institutes 21
Candidiasis - Companies Involved in Therapeutics Development 22
Amplyx Pharmaceuticals, Inc. 22
Bakker Medical Srl 23
Biomar Microbial Technologies 24
Cellceutix Corporation 25
Cidara Therapeutics, Inc. 26
Daewoong Pharmaceutical Co., Ltd. 27
General Biologicals Corporation 28
Grupo Ferrer Internacional, S.A. 29
Hsiri Therapeutics, LLC 30
Nanomerics Ltd 31
Novabiotics Limited 32
NovaDigm Therapeutics, Inc. 33
Onxeo SA 34
Panacela Labs, Inc. 35
Scynexis, Inc. 36
Sealife PHARMA GMBH 37
TGV-Laboratories 38
Viamet Pharmaceuticals, Inc. 39
Wellstat Vaccines, LLC 40
Candidiasis - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
61894700 - Drug Profile 50
AC-17 - Drug Profile 51
amphotericin b - Drug Profile 52
amphotericin B - Drug Profile 53
amphotericin B - Drug Profile 54
APX-001 - Drug Profile 55
arasertaconazole - Drug Profile 56
Candida vaccine - Drug Profile 57
candidiasis vaccine - Drug Profile 58
CD-101 - Drug Profile 59
CTIX-1502 - Drug Profile 61
DWP-06081 - Drug Profile 62
Forazoline A - Drug Profile 63
KSL-W - Drug Profile 64
MH-010 - Drug Profile 65
miconazole nitrate - Drug Profile 66
Monoclonal Antibodies to Target Fba for Candidiasis - Drug Profile 67
mutanobactins - Drug Profile 68
Myc-102 - Drug Profile 69
NDV-3 - Drug Profile 70
NDV-3A - Drug Profile 72
NP-339 - Drug Profile 73
obliquumol - Drug Profile 74
PAC-113 - Drug Profile 75
pegylated amphotericin B - Drug Profile 77
PMX-1408 - Drug Profile 78
PMX-1570 - Drug Profile 80
PMX-1576 - Drug Profile 81
PMX-1591 - Drug Profile 82
PMX-1625 - Drug Profile 83
PMX-519 - Drug Profile 84
PMX-70004 - Drug Profile 85
Prof-002 - Drug Profile 86
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 87
SCY-078 - Drug Profile 89
SLP-0901 - Drug Profile 91
SLP-0904 - Drug Profile 92
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 93
Small Molecule for Fungal Infections - Drug Profile 94
Small Molecule for Systemic Candidiasis - Drug Profile 95
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 96
Small Molecules for Candidiasis - Drug Profile 97
Small Molecules for Candidiasis - Drug Profile 98
Small Molecules for Candidiasis - Drug Profile 99
Small Molecules for Fungal Infections - Drug Profile 100
Small Molecules for Fungal Infections - Drug Profile 101
Synthetic Peptide for Multi-Drug Resistant Microbial Infections - Drug Profile 102
VT-1161 - Drug Profile 103
XELRYX-3 - Drug Profile 105
Candidiasis - Recent Pipeline Updates 106
Candidiasis - Dormant Projects 120
Candidiasis - Discontinued Products 124
Candidiasis - Product Development Milestones 125
Featured News & Press Releases 125
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 132
Disclaimer 133

List of Tables
Number of Products under Development for Candidiasis, H1 2016 13
Number of Products under Development for Candidiasis - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Comparative Analysis by Unknown Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2016 25
Candidiasis - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 26
Candidiasis - Pipeline by Bakker Medical Srl, H1 2016 27
Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2016 28
Candidiasis - Pipeline by Cellceutix Corporation, H1 2016 29
Candidiasis - Pipeline by Cidara Therapeutics, Inc., H1 2016 30
Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 31
Candidiasis - Pipeline by General Biologicals Corporation, H1 2016 32
Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 33
Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H1 2016 34
Candidiasis - Pipeline by Nanomerics Ltd, H1 2016 35
Candidiasis - Pipeline by Novabiotics Limited, H1 2016 36
Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2016 37
Candidiasis - Pipeline by Onxeo SA, H1 2016 38
Candidiasis - Pipeline by Panacela Labs, Inc., H1 2016 39
Candidiasis - Pipeline by Scynexis, Inc., H1 2016 40
Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2016 41
Candidiasis - Pipeline by TGV-Laboratories, H1 2016 42
Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 43
Candidiasis - Pipeline by Wellstat Vaccines, LLC, H1 2016 44
Assessment by Monotherapy Products, H1 2016 45
Number of Products by Stage and Target, H1 2016 47
Number of Products by Stage and Mechanism of Action, H1 2016 49
Number of Products by Stage and Route of Administration, H1 2016 51
Number of Products by Stage and Molecule Type, H1 2016 53
Candidiasis Therapeutics - Recent Pipeline Updates, H1 2016 110
Candidiasis - Dormant Projects, H1 2016 124
Candidiasis - Dormant Projects (Contd..1), H1 2016 125
Candidiasis - Dormant Projects (Contd..2), H1 2016 126
Candidiasis - Dormant Projects (Contd..3), H1 2016 127
Candidiasis - Discontinued Products, H1 2016 128